These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33520701)

  • 1. A Comprehensive Prognostic and Immune Analysis of SLC41A3 in Pan-Cancer.
    Liu J; Zhang S; Dai W; Xie C; Li JC
    Front Oncol; 2020; 10():586414. PubMed ID: 33520701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation.
    Huang S; Tan C; Zheng J; Huang Z; Li Z; Lv Z; Chen W; Chen M; Yuan X; Chen C; Yan Q
    Immunobiology; 2024 Jul; 229(5):152836. PubMed ID: 39018675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response evaluation.
    Liu J; Chen Z; Zhao P; Li W
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32648580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across¬†multiple¬†cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
    Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
    Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
    [No Abstract]   [Full Text] [Related]  

  • 7. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-Cancer Integrated Analysis of HSF2 Expression, Prognostic Value and Potential Implications for Cancer Immunity.
    Chen F; Fan Y; Liu X; Zhang J; Shang Y; Zhang B; Liu B; Hou J; Cao P; Tan K
    Front Mol Biosci; 2021; 8():789703. PubMed ID: 35087869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
    Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.
    Liu J; Li W; Wu L
    Front Pharmacol; 2022; 13():950156. PubMed ID: 36046831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-Associated Protein Is a Potential Prognostic Biomarker and Is Correlated With Immune Infiltration in Liver Hepatocellular Carcinoma: A Pan-Cancer Analysis.
    Ju Q; Li XM; Zhang H; Zhao YJ
    Front Mol Biosci; 2020; 7():573619. PubMed ID: 33240929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
    Dong X; Liu T; Li Z; Zhai Y
    Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analysis from multi-omics data reveals AAMP as an unfavourable prognostic marker.
    Wang Y; Liu T; Zhang K; Huang RH; Jiang L
    Eur J Med Res; 2023 Jul; 28(1):258. PubMed ID: 37501187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 18. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis Revealed
    Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
    J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ke P; Bao X; Liu C; Zhou B; Huo M; Chen Y; Wang X; Wu D; Ma X; Liu D; Chen S
    Transl Cancer Res; 2022 Oct; 11(10):3491-3505. PubMed ID: 36388050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.